Cargando…
Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
BACKGROUND: Approximately 10–15% of ovarian carcinomas (OC) are attributed to inherited susceptibility, the majority of which are due to mutations in BRCA1 or BRCA2 (BRCA1/2). These patients display superior clinical outcome, including enhanced sensitivity to platinum-based chemotherapy. Here, we se...
Autores principales: | Hollis, Robert L., Meynert, Alison M., Churchman, Michael, Rye, Tzyvia, Mackean, Melanie, Nussey, Fiona, Arends, Mark J., Sims, Andrew H., Semple, Colin A., Herrington, C. Simon, Gourley, Charlie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753521/ https://www.ncbi.nlm.nih.gov/pubmed/29298688 http://dx.doi.org/10.1186/s12885-017-3981-2 |
Ejemplares similares
-
Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse
por: Hollis, Robert L., et al.
Publicado: (2019) -
Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification
por: Hollis, Robert L., et al.
Publicado: (2021) -
Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma
por: Hollis, Robert L., et al.
Publicado: (2019) -
Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma
por: Hollis, Robert L., et al.
Publicado: (2022) -
Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome
por: Hollis, Robert L., et al.
Publicado: (2020)